• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

public offering

Biotech

Day One spends day 2 hitting up public markets for $150M

Just two days after Day One doubled shares on a data drop for its pediatric brain cancer drug, the biotech is circling up to raise some cash.
Gabrielle Masson Jun 15, 2022 11:16am

Zai Lab aims for $750M to bankroll licensing deals

Apr 20, 2021 3:30pm

Annexon, AlloVir gun for $100M IPOs

Jul 7, 2020 8:05am

Twist Bioscience nets $140M plus a slew of new DNA partnerships

Feb 26, 2020 12:03pm

Axovant buys more gene therapies, looking toward a busy 2019

Dec 14, 2018 7:42am

AI data miner Sensyne Health looks to go public with $77M listing

Aug 7, 2018 8:46pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy